<DOC>
	<DOCNO>NCT00368069</DOCNO>
	<brief_summary>This safety efficacy study Keppra® extend release formulation - XR patient epilepsy .</brief_summary>
	<brief_title>A Study Look Efficacy Safety Keppra® Extended Release Formulation - XR</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<criteria>Patients confirm diagnosis refractory epilepsy Patients must receive 1 3 concomitant AntiEpileptic Drugs ( AED ) . Female patient without childbearing potential . Female patient childbearing potential eligible use medically accept nonhormonal contraceptive method . Seizures occur cluster Status epilepticus within 3 month Visit 1 . History nonepileptic seizure . Known allergic reaction intolerance pyrrolidine derivative and/or excipients . Pregnant lactating woman . Any woman childbearing potential use medically accept , nonhormonal method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Keppra® XR</keyword>
	<keyword>Levetiracetam XR</keyword>
	<keyword>Extended release</keyword>
</DOC>